Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Nivolumab in Advanced Biliary Tract Cancer
NCT03639935Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rucaparib and nivolumab in biliary tract cancer (BTC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Proportion of Patients Alive and Without Radiological or Clinical Progression at 4 Months. Started Mar 2019; status: completed.
02
Drugs
rucaparibnivolumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03639935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639935.